AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01949467
Drug: iron fumarate
RxNorm normalized name: iron fumarate
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.
Trial: NCT01030081
Drug: Nifedipine GITS (Adalat® XL 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg
Trial: NCT00125346
Drug: Tobramycin Inhalation Powder
RxNorm normalized name: Tobramycin Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00220779
Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00220779
Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02080624
Drug: Drug: Topical Rapamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study.~A medical history, which involves questions about your health history, any medications you are taking or plan to take, any allergies and the treatments you received for your CM.~A physical exam, during which you will be asked about any problems that you might be having. Additionally, your clinician will check your vital signs (blood pressure, heart rate, weight and height). The doctor will also evaluate your performance status, which indicates how much your illness affects your activity level.~Blood tests, which will be done to make sure your hemogram, triglyceride and cholesterol levels are normal.~A pregnancy test for females will be done to check that you are not pregnant. If theses tests show that you are eligible to participate in the research study, you will begin the study treatment.
Trial: NCT00345644
Drug: risedronate placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for risedronate tablets (once a week dose)
Trial: NCT00328302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03562923
Drug: Test Product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder
Trial: NCT03562923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Product
Trial: NCT00395343
Drug: Comparator : placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
Trial: NCT02842554
Drug: Drug Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00966875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous
Trial: NCT00689117
Drug: Clindamycin Gel (clindamycin )
RxNorm normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
Trial: NCT00689117
Drug: Tretinoin Gel (tretinoin)
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks
Trial: NCT00689117
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
Trial: NCT00970385
Drug: CHOP21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP regimen:~* cyclophosphamide 750 mg/m2 intravenously (IV) day 1~* doxorubicin 50 mg/m2 IV day 1~* vincristine 1,4 mg/m2 (maximum 2 mg) day 1~* prednisone 100 mg/m2/D from D1 to D5.
Trial: NCT00970385
Drug: VIP/ABVD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIP regimen:~* etoposide 100 mg/m2/D IV from D1 to D3~* ifosfamide 1000 mg/m2/D from D1 to D5~* cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD regimen:~* doxorubicin50 mg/m2/D on D1 and D14~* bleomycin 10 mg/m2/D~* vinblastine 10 mg/m2/D~* dacarbazine 375 mg/m2/D
Trial: NCT03706547
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300mg/m2/d
Trial: NCT01048411
Drug: Naja-comp.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: homeopathic remedy
Trial: NCT01048411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. injection of NaCl-solution three times a week
Trial: NCT03170271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
Trial: NCT04395053
Drug: SHR1459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TR group:~The first period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h.~RT group:~The first period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h.
Trial: NCT00511394
Drug: 20% Human Albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 100 mL of 20% Albumin over 3 hours
Trial: NCT00511394
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 100 mL of Normal Saline
Trial: NCT00712400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
Trial: NCT03503513
Drug: Gentamicin Sulfate
RxNorm normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin is compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Pharmacy mails participants treatment drug. Once received, participants will do daily instillations of 30 milliliters of solution after catheterizing their bladder at night.
Trial: NCT01170039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matched placebo pill will be given twice a day for 8 weeks.
Trial: NCT03400267
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
Trial: NCT01906801
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03112954
Drug: Buccal-relaxant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.
Trial: NCT03112954
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
Trial: NCT02299739
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
Trial: NCT03635021
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin 85 mg/m2 administered by IV infusion over 120 minutes on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2
Trial: NCT03635021
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46-48 hours on Days 1 and 2
Trial: NCT00637949
Drug: rofecoxib
RxNorm normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg, oral, daily over 6 weeks
Trial: NCT00935415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules of matching placebo
Trial: NCT03660059
Drug: Plaebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01797809
Drug: EV/DNG (Qlaira, BAY86-5027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.
Trial: NCT04034251
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1-15 of each 3-week cycle: oral capecitabine (825 mg/m\^2) to be taken twice a day starting the evening of Day 1 of each cycle until the morning of Day 15, followed by a 7-day rest period during each 3-week cycle.
Trial: NCT02739633
Drug: Genexol-PM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
Trial: NCT01258569
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg oral 30-300 min pre-op then BID up to 7 days (or 15 doses)
Trial: NCT04263584
Drug: R-CHOP Chemotherapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunochemotherapy
Trial: NCT01267227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo by mouth twice daily for 6 to 8 weeks
Trial: NCT03745599
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
Trial: NCT03745599
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
Trial: NCT03236155
Drug: opioid pain pills
RxNorm normalized name: Arthriten Inflammatory Pain Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient will receive their pain pill prescription
Trial: NCT02561767
Drug: Induction therapy (ATG or Basiliximab)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.
Trial: NCT02561767
Drug: Maintenance therapy (Low-dose CNI + MPA + steroids)
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
Trial: NCT01643785
Drug: Second-line quadruple therapy with endonase
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare Second-line quadruple therapy w/o pronase (endonase)
Trial: NCT02366364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of placebo consumption on Day 1
Trial: NCT02745145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received Placebo matched to Abituzumab administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
Trial: NCT01208753
Drug: GLPG0555
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two different aqueous formulations
Trial: NCT01208753
Drug: GLPG0555 aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined
Trial: NCT01356290
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50-400mg, oral bid, daily, 1 year
Trial: NCT01356290
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
Trial: NCT01208753
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
Trial: NCT04367051
Drug: Withdrawal of Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.
Trial: NCT04367051
Drug: Continuation of spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.
Trial: NCT00714025
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 10mg, daily, PO
Trial: NCT00568464
Drug: VCR, CTX, ADM; IFO, VP-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
Trial: NCT00275132
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo PO daily
Trial: NCT02844062
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/m\^2 d1-3
Trial: NCT03595618
Drug: GLPG1972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablets of GLPG1972 for oral use.
Trial: NCT03595618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablets of matching placebo for oral use.
Trial: NCT04589624
Drug: Hyperpolarized Carbon C 13 Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01269671
Drug: Melatonin, Peppermint Oil (mentharil), and Simethicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
Trial: NCT03332212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 Weeks
Trial: NCT01410344
Drug: Cyclophosphamide and Total Body Irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen:~* Days -7 to -4: TBI (total dose of 1200-1420 cGy)~* Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg)~Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight.
Trial: NCT01980589
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.
Trial: NCT01912391
Drug: Placebo (for Selegiline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
Trial: NCT04874701
Drug: Capsimax
RxNorm normalized name: Capsinac KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg
Trial: NCT03361540
Drug: ASP8302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP8302 will be administered orally.
Trial: NCT03361540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally.
Trial: NCT04801264
Drug: 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
Trial: NCT03708887
Drug: Low dose omega-3 fatty acid supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year
Trial: NCT03708887
Drug: High dose omega-3 fatty acid supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
Trial: NCT03708887
Drug: Control drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules,3 g/d by mouth for 1 year
Trial: NCT01552798
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
Trial: NCT01552798
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
Trial: NCT01552798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
Trial: NCT00260364
Drug: Capecitabine orally days 1 -21
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03948477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT04600271
Drug: Colloid Blood Volume Expanders
RxNorm normalized name: BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exposure
Trial: NCT04600271
Drug: Diuretic
RxNorm normalized name: Diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exposure
Trial: NCT04600271
Drug: Non-Steroidal Anti-Inflammatory Analgesics
RxNorm normalized name: NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exposure
Trial: NCT04993339
Drug: OOC
RxNorm normalized name: isooctane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The OOC will be mixed with autologous 5cc of platelet rich plasma (PRP), and then injected using a syringe into both tibia and femoral tunnels
Trial: NCT01009892
Drug: Codeine Sulfate
RxNorm normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00552747
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules placebo
Trial: NCT02992197
Drug: Placebo (for Rotarix dose 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water to provide volume equivalent as a second dose of Rotarix
Trial: NCT01692470
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
Trial: NCT03932825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An 1-hour session of mixed oxygen-air gas(inspired oxygen concentration \~50%)